Evolution of blood–brain barrier in brain diseases and related systemic nanoscale brain-targeting drug delivery strategies

Autor:	Liang Han, Chen Jiang
Jazyk:	angličtina
Rok vydání:	2021
Předmět:	PSMA prostate-specific membrane antigen Gd gadolinium BACE1 β-secretase 1 MMP9 metalloproteinase-9 PLGA poly(lactic-co-glycolic acid) Disease Review Aβ amyloid beta ICAM-1 intercellular adhesion molecule-1 KCa calcium-dependent potassium channels PD Parkinson's disease LDL low density lipoprotein PEG polyethyleneglycol Epilepsy 0302 clinical medicine P-gp P-glycoprotein Medicine LRP1 LDLR-related protein 1 General Pharmacology Toxicology and Pharmaceutics BBB blood–brain barrier siRNA short interfering RNA 0303 health sciences ZO1 zona occludens 1 LAT1 L-type amino acid transporter 1 LDLR LDL receptor RBC red blood cell AMT alpha-methyl-l-tryptophan DTPA-Gd Gd-diethyltriaminepentaacetic acid RAGE receptor for advanced glycosylation end products VEGF vascular endothelial growth factor Drug delivery systems KATP ATP-sensitive potassium channels medicine.anatomical_structure TJ tight junction 030220 oncology & carcinogenesis Drug delivery cardiovascular system AD Alzheimer's disease Brain diseases RMT receptor-mediated transcytosis Traumatic brain injury Brain tumor BDNF brain derived neurotrophic factor Brain-targeting TfR transferrin receptor RM1-950 Blood–brain barrier TBI traumatic brain injury MFSD2A major facilitator superfamily domain-containing protein 2a 03 medical and health sciences ROS reactive oxygen species EPR enhanced permeability and retention NPs nanoparticles 030304 developmental biology CMT carrier-mediated transportation PEG-PLGA polyethyleneglycol-poly(lactic-co-glycolic acid) business.industry LFA-1 lymphocyte function associated antigen-1 GLUT1 glucose transporter-1 medicine.disease tPA tissue plasminogen activator Brain targeting BTB blood–brain tumor barrier nervous system Nanoparticles Nasal administration Therapeutics. Pharmacology business Neuroscience MRI magnetic resonance imaging
Zdroj:	Acta Pharmaceutica Sinica B, Vol 11, Iss 8, Pp 2306-2325 (2021) Acta Pharmaceutica Sinica. B
ISSN:	2211-3835
Popis:	Blood–brain barrier (BBB) strictly controls matter exchange between blood and brain, and severely limits brain penetration of systemically administered drugs, resulting in ineffective drug therapy of brain diseases. However, during the onset and progression of brain diseases, BBB alterations evolve inevitably. In this review, we focus on nanoscale brain-targeting drug delivery strategies designed based on BBB evolutions and related applications in various brain diseases including Alzheimer's disease, Parkinson's disease, epilepsy, stroke, traumatic brain injury and brain tumor. The advances on optimization of small molecules for BBB crossing and non-systemic administration routes (e.g., intranasal treatment) for BBB bypassing are not included in this review. Graphical abstract Blood–brain barrier (BBB) is evolving during the onset and progression of brain diseases. BBB evolution-based nanoscale brain-targeting drug delivery strategies are summarized in this review for various brain diseases.Image 1
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a05eff9f72ac70fe48cb5ed9a111b5b http://www.sciencedirect.com/science/article/pii/S2211383520308522 Zobrazit plný text záznamu